α2β1 Integrin Specific Inhibitor BTT-3033 Promotes Paclitaxel-induced Apoptosis in Human Ovarian Cancer Cells

Overview

Journal Res Pharm Sci

Specialty Chemistry

Date 2024 Dec 18

PMID 39691300

Authors

Zeinab Babaei

Mahdi Amani

Mohsen Minaiyan

Seyedeh Sara Ghorbanhosseini

Mahmoud Aghaei

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: The new plan of using molecular targeted agents in combination with cytotoxic drugs may represent a promising strategy to increase the efficacy of chemotherapy. Hence, we examined whether α2β1 integrin-specific inhibitor, BTT-3033, could modulate the susceptibility of OVCAR3 and SKOV3 ovarian cancer cells to paclitaxel (PTX).

Experimental Approach: Ovarian cancer cell lines were treated with BTT-3033 and different concentrations of PTX. To determine the mechanisms involved in the PTX/BTT-3033 combination-induced cell death, cell viability, apoptosis, reactive oxygen species (ROS) production, mitochondrial membrane potential (MMP), and caspase-3 activity were evaluated.

Findings/results: Both BTT-3033 (≥ 1 μM) and PTX (≥ 0.01 μM) suppressed the proliferation of OVCAR3 and SKOV3 cells in a concentration-related manner. Pretreatment with BTT-3033 (1 μM), followed by PTX-induced synergistic antiproliferative effects, decreased the IC values of PTX from 0.45 to 0.03 μM in OVCAR3 and 0.35 to 0.02 μM in SKOV3 cells. All of the coefficients of drug interaction for various PTX and BTT-3033 combinations were found to be less than 1. Moreover, PTX/BTT-3033 combination induced more apoptotic cells (from 4.2% to 87.0% in OVCAR3 and 2.4% to 88.5% in SKOV3) than PTX alone. Combination therapy also decreased MMP and increased the caspase-3 activity. Additionally, we found that the PTX/BTT-3033 combination enhanced ROS production in OVCAR3 and SKOV3 cells.

Conclusion And Implications: BTT-3033 has demonstrated the ability to enhance the susceptibility of ovarian cancer cells to PTX by inducing MMP loss, ROS production, and mitochondrial apoptosis, therefore this combination therapy might represent a promising strategy for ovarian cancer treatment.

References

Naci D, Vuori K, Aoudjit F . Alpha2beta1 integrin in cancer development and chemoresistance. Semin Cancer Biol. 2015; 35:145-53. DOI: 10.1016/j.semcancer.2015.08.004. View

Zargar Balajam N, Shabani M, Aghaei M . Galectin-9 inhibits cell proliferation and induces apoptosis in Jurkat and KE-37 acute lymphoblastic leukemia cell lines caspase-3 activation. Res Pharm Sci. 2021; 16(6):612-622. PMC: 8562407. DOI: 10.4103/1735-5362.327507. View

Czogalla B, Dotzer K, Sigruner N, von Koch F, Brambs C, Anthuber S . Combined Expression of HGFR with Her2/neu, EGFR, IGF1R, Mucin-1 and Integrin α2β1 Is Associated with Aggressive Epithelial Ovarian Cancer. Biomedicines. 2022; 10(11). PMC: 9687566. DOI: 10.3390/biomedicines10112694. View

Zhang L, Zou W . Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway. Mol Med Rep. 2015; 12(6):7869-76. PMC: 4758278. DOI: 10.3892/mmr.2015.4443. View

Scalici J, Harrer C, Allen A, Jazaeri A, Atkins K, McLachlan K . Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol. 2014; 132(2):455-61. PMC: 3939448. DOI: 10.1016/j.ygyno.2013.12.031. View

Shahali A, Ghanadian M, Jafari S, Aghaei M . Mitochondrial and caspase pathways are involved in the induction of apoptosis by nardosinen in MCF-7 breast cancer cell line. Res Pharm Sci. 2018; 13(1):12-21. PMC: 5772077. DOI: 10.4103/1735-5362.220963. View

Aoudjit F, Vuori K . Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001; 20(36):4995-5004. DOI: 10.1038/sj.onc.1204554. View

Cohen E, Tendler T, Lu H, Hansen C, Kertsman J, Kurtsman J . Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling. Anticancer Res. 2013; 33(2):379-86. View

Zheng W, Ge D, Meng G . Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer. Cell Biol Int. 2019; 44(2):610-620. DOI: 10.1002/cbin.11261. View

10.

Sherman-Baust C, Becker K, Wood Iii W, Zhang Y, Morin P . Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res. 2011; 4(1):21. PMC: 3259089. DOI: 10.1186/1757-2215-4-21. View

11.

Li X, Ishihara S, Yasuda M, Nishioka T, Mizutani T, Ishikawa M . Lung cancer cells that survive ionizing radiation show increased integrin α2β1- and EGFR-dependent invasiveness. PLoS One. 2013; 8(8):e70905. PMC: 3738636. DOI: 10.1371/journal.pone.0070905. View

12.

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J . The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12:985363. PMC: 9597512. DOI: 10.3389/fonc.2022.985363. View

13.

Cooper J, Giancotti F . Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3):347-367. PMC: 6684107. DOI: 10.1016/j.ccell.2019.01.007. View

14.

Nissinen L, Koivunen J, Kapyla J, Salmela M, Nieminen J, Jokinen J . Novel α2β1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation. J Biol Chem. 2012; 287(53):44694-702. PMC: 3531784. DOI: 10.1074/jbc.M111.309450. View

15.

Hodkinson P, Elliott T, Wong W, Rintoul R, Mackinnon A, Haslett C . ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 2006; 13(10):1776-88. DOI: 10.1038/sj.cdd.4401849. View

16.

Aoudjit F, Vuori K . Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012; 2012:283181. PMC: 3332161. DOI: 10.1155/2012/283181. View

17.

Ye Y, Zhang T, Yuan H, Li D, Lou H, Fan P . Mitochondria-Targeted Lupane Triterpenoid Derivatives and Their Selective Apoptosis-Inducing Anticancer Mechanisms. J Med Chem. 2017; 60(14):6353-6363. DOI: 10.1021/acs.jmedchem.7b00679. View

18.

Jafari S, Nazri A, Shabani M, Zargar Balajam N, Aghaei M . Galectin-9 induces apoptosis in OVCAR-3 ovarian cancer cell through mitochondrial pathway. Res Pharm Sci. 2019; 13(6):557-565. PMC: 6288986. DOI: 10.4103/1735-5362.245967. View

19.

Pistritto G, Trisciuoglio D, Ceci C, Garufi A, DOrazi G . Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016; 8(4):603-19. PMC: 4925817. DOI: 10.18632/aging.100934. View

20.

Jakubzig B, Baltes F, Henze S, Schlesinger M, Bendas G . Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells-Deciphering Novel Potential Targets for a Cell Sensitization. Cancers (Basel). 2018; 10(12). PMC: 6315379. DOI: 10.3390/cancers10120495. View